Clinical trial · Observational
Study of Myocardial Function by Speckle Tracking After Cancer Treatment With Anthracyclines in Childhood
NCT02893787CI-TRIAL-00057086SPECKLEANTHRAcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main goal of this study is to compare the values of echocardiographic parameters obtained by Speckle Traking analysis on myocardial function among patients under 18 years treated with anthracyclines in childhood, with healthy age and sex mached volunteers.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chilhood Cancers | — | UNRESOLVED | — |
| Echographic Parameters Obtaind by Speckle Tracking | — | UNRESOLVED | — |
| Myocardial Function | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Speckle Tracking Echocardiography | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patients treated with anthracyclines in childhood
- interventionNames
- Other: Speckle Tracking Echocardiography
- label
- Healthy volunteers
- interventionNames
- Other: Speckle Tracking Echocardiography
Primary outcomes (1)
- measure
- Echocardiographic parameters obtained by Speckle Tracking
- timeFrame
- Immediat
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: * Patient treated between 0 and 18 with anthracyclines for malignancy * Discontinuation of treatment with chemotherapy for over 1 year * Patient in remission of his malignancy * Lack of heart or lung disease associated * No opposition patient and legal guardian * Patient younger than 18 at the time of the study. Exclusion criteria: * Progressive malignant pathology. * Cardiac, lung or muscle chronic diseases, etiology other than secondary to treatment with anthracyclines * Refusal to participate in the study * Poor echogenicity
References
Publications (1)
- RESULTAmedro P, Vincenti M, Abassi H, Lanot N, De La Villeon G, Guillaumont S, Gamon L, Mura T, Lopez-Perrin K, Haouy S, Sirvent A, Cazorla O, Vergely L, Lacampagne A, Avesani M, Sirvent N, Saumet L. Use of speckle tracking echocardiography to detect late anthracycline-induced cardiotoxicity in childhood cancer: A prospective controlled cross-sectional study. Int J Cardiol. 2022 May 1;354:75-83. doi: 10.1016/j.ijcard.2022.02.012. Epub 2022 Feb 12. PMID 35167907